Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis

Article Rheumatology

Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials

Dalton Sholter et al.

Summary: The study shows that rheumatoid arthritis patients treated with baricitinib who achieved MCID improvements at week 4 and week 12 were able to maintain those improvements over time and achieve substantial PRO responses quickly.

RHEUMATOLOGY AND THERAPY (2022)

添加到收藏夹

Article Rheumatology

Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis

Serena Bugatti et al.

Summary: This study found that in the early stages of rheumatoid arthritis, particularly in patients who test positive for autoantibodies, inflammatory markers are directly correlated with the Patient Global Assessment. However, in patients with established rheumatoid arthritis, there is no independent correlation between inflammatory markers and the Patient Global Assessment, regardless of disease activity and autoantibody status.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Review Immunology

The autoimmune aetiology of unexplained chronic pain

Andreas Goebel et al.

Summary: Chronic pain is a major cause of disability worldwide, but its etiology and treatment methods are still uncertain. Research has found that autoimmune factors may be related to certain chronic pain conditions, caused by antibody-mediated autoimmune mechanisms. These findings suggest that antibody-mediated autoimmune mechanisms may play an important role in multiple conditions and further research is needed to elucidate the molecular and cellular details.

AUTOIMMUNITY REVIEWS (2022)

添加到收藏夹

Article Rheumatology

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

Kim Lauper et al.

Summary: This study compared the effectiveness of four different second-line therapies of rheumatoid arthritis and found that the overall drug discontinuation and 1-year response rates of JAKi and IL-6i were similar to TNFi. JAKi were more often discontinued for adverse events and less for ineffectiveness compared to TNFi.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies

Clifton O. Bingham et al.

Summary: This study investigated the effects of Filgotinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis. The results showed that Filgotinib improved symptoms, quality of life, and work productivity in different patient populations.

ARTHRITIS RESEARCH & THERAPY (2022)

添加到收藏夹

Article Rheumatology

Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis

Irina Gessl et al.

Summary: Clinical tenderness may not always indicate active inflammation in RA, PsA, and OA. While tenderness in early arthritis may be more associated with inflammation, established disease is better explained by joint damage and malalignment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Rheumatology

Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis

Maya H. Buch et al.

Summary: This review focuses on two types of refractory rheumatoid arthritis (RA) patients: those with persistent inflammatory refractory RA (PIRRA) and those with non-inflammatory refractory RA (NIRRA). Identifying individuals with predominant PIRRA or NIRRA is crucial for informing distinct treatment and management approaches for refractory RA.

NATURE REVIEWS RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE

Vibeke Strand et al.

Summary: In MTX-IR patients with RA, treatment with upadacitinib resulted in statistically significant and clinically meaningful improvements in PROs equivalent to or greater than with adalimumab.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

The Jak/STAT pathway: A focus on pain in rheumatoid arthritis

Lee S. Simon et al.

Summary: Pain in rheumatoid arthritis can be treated by cytokines regulated by the Jak/STAT pathway, which play important roles in regulating inflammation and pain mechanisms.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)

添加到收藏夹

Editorial Material Rheumatology

Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis

Luca Quartuccio et al.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis

Serena Bugatti et al.

Summary: In early rheumatoid arthritis, Boolean remission is more often missed due to persistent swollen joints. However, barriers to full remission vary depending on the autoantibody status.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)

添加到收藏夹

Article Rheumatology